Logo

H3 Biomedicine

Bristol-Myers Squibb, H3 Biomedicine Form Cancer Immunotherapy Alliance

H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

Foundation Medicine, H3 Biomedicine Partner to ID Cancer Drug Targets

The partnership marries Foundation's genomic knowledgebase with H3's drug discovery engine and computational biology platform.

BGI, H3 Biomedicine Strike Sequencing Data Publishing Pact

NEW YORK (GenomeWeb News) – BGI and H3 Biomedicine today announced they will sequence and publish data from next-generation sequencing-based research on pre-clinical cancer models.

H3 Biomedicine's CEO Says Bioinformatics Plays 'Big Role' in Oncology Drug Discovery Efforts
Premium

This article has been updated to clarify the tools being co-developed by H3 Biomedicine and Sage Bionetworks

H3 Biomedicine, Sage Partner on Genomic Profiling Software

NEW YORK (GenomeWeb News) – Cancer biotherapeutics developer H3 Biomedicine said today that it will partner with Sage Bionetworks to develop new software aimed at supporting its efforts to predict human responses to certain drugs.